Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-FU, Oxaliplatin, Liposomal Irinotecan and Immunotherapy in 1st Line Advanced Esophageal and Gastric Adenocarcinoma
NCT04150640Phase 2Recruiting
- Sponsor
- University of Wisconsin–Madison
- Start
- Jul 2020
- Primary completion
- Dec 2027
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nanoliposomal irinotecan in esophageal adenocarcinoma (EAC), gastric adenocarcinoma, sponsored by University of Wisconsin–Madison. Started Jul 2020; status: recruiting.
02
Drugs
nanoliposomal irinotecan
03
Conditions
esophageal adenocarcinoma (EAC)gastric adenocarcinoma
Beyond the preview
Go deeper on NCT04150640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04150640.